PriceTargets.com logo

Medicines - MDCO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$84.90 As of 01/6/2020 01:00 AM ET
+0 (0.00%)
Get New Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDCO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medicines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $84.90.

This chart shows the closing price for MDCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Medicines. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$78.00 ➝ $85.00Low
11/26/2019Chardan CapitalDowngradeBuy ➝ NeutralLow
11/25/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00Low
11/25/2019OppenheimerDowngradeOutperform ➝ Hold$68.00 ➝ $85.00High
11/25/2019Robert W. BairdDowngradeOutperform ➝ Neutral$100.00 ➝ $85.00Medium
11/25/2019CowenReiterated RatingBuy$60.00Low
11/20/2019CitigroupReiterated RatingHold$59.00High
11/19/2019Chardan CapitalReiterated RatingBuy$100.00Low
11/18/2019CowenReiterated RatingBuy$60.00High
10/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$44.00 ➝ $50.00High
10/2/2019B. RileyBoost TargetBuy$74.00 ➝ $95.00Low
9/17/2019CitigroupDowngradeBuy ➝ Neutral$55.00Low
9/3/2019Roth CapitalSet TargetBuy$72.00Low
9/3/2019SVB LeerinkReiterated RatingBuyLow
9/3/2019JPMorgan Chase & Co.Boost TargetOverweight$39.00 ➝ $49.00Medium
9/3/2019OppenheimerBoost TargetOutperform$52.00 ➝ $60.00High
9/3/2019CitigroupBoost TargetBuy ➝ Buy$48.00 ➝ $55.00High
9/2/2019Piper Sandler CompaniesReiterated RatingOverweight ➝ Positive$142.00 ➝ $145.00High
8/26/2019B. RileySet TargetBuy$61.00Low
8/26/2019Chardan CapitalSet TargetBuy$90.00Low
8/26/2019Roth CapitalSet TargetBuy$72.00Low
8/26/2019CowenSet TargetBuy$48.00Low
8/26/2019JPMorgan Chase & Co.Set TargetBuy$39.00Low
8/26/2019Bank of AmericaReiterated RatingBuy$51.00High
8/4/2019CowenSet TargetBuy$46.00Low
7/15/2019OppenheimerSet TargetBuy$48.00Low
7/9/2019Bank of AmericaReiterated RatingBuy ➝ Buy$36.00 ➝ $43.00Medium
5/28/2019B. RileySet TargetBuy$61.00Medium
5/20/2019B. RileySet TargetBuy$38.00Low
5/20/2019Robert W. BairdReiterated RatingOverweight$80.00 ➝ $110.00High
4/26/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00 ➝ $90.00High
4/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $55.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Medicines logo
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $84.90
Low: $84.90
High: $84.90

50 Day Range

MA: $84.90
Low: $84.90
High: $84.90

52 Week Range

Now: $84.90
Low: $17.81
High: $84.98

Volume

N/A

Average Volume

9,546,600 shs

Market Capitalization

$6.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicines?

The following Wall Street research analysts have issued stock ratings on Medicines in the last twelve months:
View the latest analyst ratings for MDCO.

What is the current price target for Medicines?

0 Wall Street analysts have set twelve-month price targets for Medicines in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medicines in the next year.
View the latest price targets for MDCO.

What is the current consensus analyst rating for Medicines?

Medicines currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDCO.

What other companies compete with Medicines?

Other companies that are similar to Medicines include Jazz Pharmaceuticals, Perrigo, Corcept Therapeutics, Elanco Animal Health and Cytokinetics. Learn More about companies similar to Medicines.

How do I contact Medicines' investor relations team?

Medicines' physical mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company's listed phone number is 973-290-6000 and its investor relations email address is [email protected]. The official website for Medicines is www.themedicinescompany.com. Learn More about contacing Medicines investor relations.